For men with prostate cancer, several treatments have become standard of care. These include hormone therapy, which reduces the levels of male hormones (androgens) that fuel the growth of prostate cancer cells. One hormone therapy medication is Lutetium Lu 177 Dotatate, which is used to treat advanced prostate cancer that has spread to other parts of the body. Another hormone therapy medication is Abiraterone, which is used to treat men with advanced prostate cancer that has not responded to other treatments. Radiation therapy is another common treatment for prostate cancer. This involves using high-energy rays to kill cancer cells. One type of radiation therapy is called stereotactic body radiation therapy (SBRT), which delivers precise, high doses of radiation to the tumor. Radiation therapy can be used alone or in combination with hormone therapy. Surgery is also an option for men with prostate cancer. Radical prostatectomy, which involves removing the prostate gland, is a common surgical procedure. This can be done using traditional open surgery or more minimally invasive approaches, such as robotic-assisted surgery.
Researchers are actively studying several new treatments for prostate cancer. One area of focus is on targeted therapies, which aim to specifically kill cancer cells while sparing healthy cells. Researchers are testing several targeted therapies, including medications that block the activity of specific proteins involved in cancer cell growth. Another area of focus is on immunotherapy, which involves using the body's own immune system to fight cancer. Researchers are testing several immunotherapies, including medications that stimulate the immune system to attack cancer cells. Researchers are also studying new combinations of existing treatments. For example, some studies are testing the combination of hormone therapy and radiation therapy to see if this approach is more effective than either treatment alone.
The evidence for new treatments for prostate cancer is at various stages of development. Some treatments are already approved and widely available, while others are still in the early stages of research. Approved treatments, such as hormone therapy and radiation therapy, have been extensively studied and have a strong track record of safety and effectiveness. These treatments are widely available and are often used as first-line treatments for men with prostate cancer. Clinical trials are testing several new treatments, including targeted therapies and immunotherapies. These trials are ongoing and are expected to provide more information about the safety and effectiveness of these new treatments. Early-stage research, including preclinical studies and Phase 1 trials, is also underway. These studies are exploring new biological targets and new approaches to treating prostate cancer.
The research landscape for prostate cancer is complex and rapidly evolving. There are many treatment options available, and researchers are actively studying new approaches to treating the disease. While there are many treatment options available, each man's situation is unique, and the best treatment approach will depend on the individual's specific needs and circumstances. Men with prostate cancer should work closely with their healthcare providers to determine the best course of treatment. The field of prostate cancer research is moving quickly, with new treatments and approaches being developed and tested all the time. This means that men with prostate cancer may have access to new and innovative treatments in the future.
AI-generated summary · last updated March 6, 2026
This trial is studying the effects of ESK981 in patients with certain types of solid tumors. The trial is currently recruiting participants. It's too early to know if ESK981 will be effective for these conditions.
The trial is currently recruiting and is in an early stage, so limited data is available.
View source →This trial is studying the use of 18F-DCFpyL to monitor prostate cancer that has come back after treatment. The trial is currently recruiting participants. It aims to learn more about how this method works for monitoring the disease.
The trial is currently recruiting and the phase is not specified, indicating it is in an early stage with limited data available.
View source →This trial is studying a combination of treatments for castration-sensitive oligometastatic prostate cancer. The trial is currently active but not recruiting new participants. Researchers are exploring the effectiveness of these treatments together.
The trial is in an early stage and not recruiting new participants, so limited data is available.
View source →This trial is studying a combination of a DNA vaccine and an anti-PD-1 monoclonal antibody for non-castrate recurrent oligometastatic prostate cancer. The trial is currently recruiting participants. It's too early to know if this treatment will be effective.
The trial is in its early stage and recruiting participants, so limited data is available.
View source →This trial is studying a new drug, AZD0516, for metastatic prostate cancer. It's looking at the drug alone and in combination with another drug, AZD9574. The trial is currently recruiting participants.
The trial is in its early stage and currently recruiting, so limited data is available.
View source →This trial is studying the effect of M1774 on a type of hard-to-treat prostate cancer. The trial is currently active but not recruiting new participants. Researchers are using various tests to evaluate the treatment's effects.
The trial is currently not recruiting new participants and is in an early stage of research.
View source →This trial is studying treatments for advanced prostate cancer that has not responded to hormonal therapy. It is comparing different combinations of medications, including radiation and immunotherapy. The trial is currently recruiting participants.
The trial is in its early stage and currently recruiting participants, so limited data is available.
View source →This trial is studying a treatment for metastatic castration-resistant prostate cancer. The study is currently recruiting participants with varying levels of kidney function. Researchers are looking at the effects of a specific treatment on this type of cancer.
The trial is in its early stage and is still recruiting participants, so limited data is available.
View source →This trial is studying the safety and effectiveness of a radiation-based treatment for metastatic prostate cancer with neuroendocrine cells. The trial is currently recruiting participants. The treatment being tested is Lutetium Lu 177 Dotatate.
The trial is in its early stages and is still recruiting participants, so limited data is available.
View source →This trial is studying the effectiveness of two immunotherapy drugs and one anti-cancer targeted drug for rare genitourinary tumors. The trial is currently recruiting participants. It's too early to know if this treatment will be effective.
The trial is still recruiting and in an early stage, so limited data is available.
View source →This trial is studying bicalutamide with or without an Akt inhibitor for previously treated prostate cancer. The trial is currently active but not recruiting new patients. Researchers are exploring the effectiveness of this combination.
The trial is currently not recruiting new patients and is in an early stage of research.
View source →This trial is studying treatments for metastatic castration-resistant prostate cancer. It is currently active but not recruiting new patients. The trial is exploring different combinations of medications to treat this type of cancer.
The trial is currently not recruiting new patients and is in an early stage of research.
View source →This trial is studying a new treatment for metastatic castration-resistant prostate cancer in Japanese participants. The trial is currently active but not recruiting new participants. Researchers are exploring the safety and effects of the treatment.
The trial is in its early stage and not recruiting new participants, so limited data is available.
View source →This trial is studying how well combined PSMA-PET/CT and MRI work for staging intermediate and high-risk prostate cancer. The trial is currently active but not recruiting new participants. The goal is to assess the effectiveness of this staging method.
The trial is active but not recruiting, and the phase is not specified.
View source →Researchers studied patients with high-risk prostate cancer who had robot-assisted surgery, looking at whether sparing nerves during surgery was safe. They found that in some cases, nerve-sparing surgery may be feasible, but the decision should be based on careful patient selection using imaging tests. The study identified factors that increase the risk of cancer returning after surgery.
This is an early study based on a retrospective analysis of patient data, and prospective studies are needed to validate the findings.
View source →Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
NCT05422794 →Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
NCT07137416 →Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer
NCT01928589 →Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
NCT05183126 →Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
NCT00310180 →Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones
NCT04090398 →Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
NCT00040352 →A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
NCT02339571 →Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
NCT03606967 →Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
NCT06058377 →